The Cooper Companies, Inc. · NASDAQ:COO
The Cooper Companies — Cooper Companies — Investor Presentation (June 2008)
24 slides from The Cooper Companies's investor presentation, Jun 9, 2008
Slide 1: Investor Presentation
Exhibit 99.1 Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including projections of Cooper’s results. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or impre
Slide 3: Company Overview
The ©Goper Company Overview
Slide 4: The Cooper Companies Company Overview
The Cooper Companies Company Overview The Cooper Companies Global medical products company Develops, manufactures and markets specialty healthcare products through its subsidiaries: CooperVision (CVI) and CooperSurgical (CSI) Headquartered in Pleasanton, CA Total Employees: 7,500 (approx) 30 countri
Slide 5: The Cooper Companies Company Overview: Sales
The Cooper Companies Company Overview FY 2007 COO Annual Sales Sales: $951M, up 11% CSI $167M CVI up 8% CSI $155M CSI CSI $125M CSI up 24% (9% organic) $109M Non-GAAP EPS*: $2.12 CVI CVI $913M CVI CVI $796M Shares outstanding (diluted): 44.7M $698M $734M Q2 FY 2008 2005 2006 2007 2008E* * 2008E repr
Slide 6: The Cooper Companies Guidance
The Cooper Companies Guidance $ in millions, except EPS and percentages FY08 YoY Proj. FY09 Guidance* Change** Guidance* CVI $895 - $930 15% CSI $165 - $170 8% TOTAL $1,060 - $1,100 14% GAAP $1.40 - $1.85 N/A Non-GAAP*** $2.10 - $2.35 N/A CapEx $160 - $170 10% $125-$140 Gross Margin*** 61% - 63% 0%
Slide 7: The Cooper Companies Current Topics
The Cooper Companies Current Topics New Products 1-Month SiH (Biofinity®) launched in June 2007. FY08 Guidance of $50-70M in sales. Proclear® 1 Day launched in US and Europe in late 2007. 2-Week SiH (Avaira™) launched in April 2008. FY08 Guidance of $8-10M in sales. Product Pipeline 1-Month SiH Tori
Slide 8: The Cooper Companies Long Term Objectives
The Cooper Companies Long Term Objectives The Cooper Companies Consistent double-digit organic revenue growth Gross margin in the low 60’s Operating margin in the low 20’s (post share-based compensation) EPS growth of 15-20% CooperVision Grow at a rate of at least 1.5x global market Become the #2 gl
Slide 9: CooperVision
Goper Visions’ aa\tie Goper
Slide 10: CooperVision Company Overview
CooperVision Company Overview CooperVision (CVI) develops, manufactures CVI Annual Sales and markets a broad range of contact lenses for the global market FY 2007 $913M $796M Sales: $796M, up 8% $698M $734M Gen II conversion materially completed Consolidated 21 warehouses in Europe and the US to thr
Slide 11: CooperVision Sales by Category
CooperVision Sales by Category All Major CVI Lens Categories Grew CVI Global Soft Lens Sales YoY in Fiscal 2Q08 By Product, 2Q FY2008 Specialty Toric Spherical Sales of $73M, up 8% YoY (Reusable) $81M 36% Silicone Multifocal Hydrogel $12M Sales of $14M, up 28% YoY 5% Spherical Cosmetic (Single Use)
Slide 12: CooperVision Sales by Region
CooperVision Sales by Region All Major CVI Geographies Grew CVI Global Soft Lens Sales YoY in Fiscal 2Q08 By Region, 2Q FY2008 Revenue by geography Americas Americas Sales of $95M, up 10% YoY $95M 43% Europe Sales of $87M, up 20% YoY Asia-Pacific Asia-Pacific $40M 18% Sales of $40M, up 38% YoY Europ
Slide 13: Global Market Statistics Competitive Dynamics
Global Market Statistics Competitive Dynamics United States Global Soft Contact Lens Market #1 J&J By Competitor, Q1 2008 #2 Cooper #3 Ciba Other #4 B&L 4% B&L Europe 15% #1 Ciba Cooper #2 Cooper JNJ 16% 42% #3 J&J #4 B&L Asia/Pac CIBA 23% #1 J&J #2 B&L #3 Ciba #4 Cooper Source: Independent Market R
Slide 14: Global Market Statistics Modality Breakdown
Global Market Statistics Modality Breakdown Americas EMEA Asia-Pac Daily: 10% Daily: 38% Daily: 57% 2-Week: 65% 2-Week: 12% 2-Week: 28% Monthly: 25% Monthly: 50% Monthly: 15% Global Daily: 34% 2-Week: 39% Monthly: 27% Source: Management estimates 14
Slide 15: Global Market Statistics Soft Lens Sales CAGR by Product
Global Market Statistics Soft Lens Sales Estimated 5-Year Sales Trend CAGR By Product CY 2007 to CY 2012E $ in millions $5,392(1) $7,287 6% (Market) 100% Specialty* Specialty* 6% 90% $1,388 $1,893 26% 26% 80% Spherical 70% Spherical (Single Use) (Single Use) 9% 60% $1,765 $2,741 33% 50% 38% 40% Sphe
Slide 16: Global Market Statistics Soft Lens Sales CAGR by Region
Global Market Statistics Soft Lens Sales Estimated 5-Year Sales Trend CAGR By Region CY 2007 to CY 2012E $ in millions $5,392(1) $7,287 6% (Market) 100% Europe* Europe* 6% 90% $1,664 $2,237 31% 31% 80% 70% Asia/Pacific Asia/Pacific 60% $1,607 $2,212 7% 30% 30% 50% 40% 30% Americas Americas $2,121 $2
Slide 17: CooperSurgical
oO GoperSuraical 7 Goper
Slide 18: CooperSurgical Company Overview
CooperSurgical Company Overview CooperSurgical (CSI) develops, CSI Annual Sales manufactures, and markets medical devices, diagnostic products and surgical instruments for gynecologists and obstetricians Leader of the fragmented US medical device segment of women’s healthcare $155M $167M $125M Holds
Slide 19: CooperSurgical Diversified Product Lines
CooperSurgical Diversified Product Lines CooperSurgical has evolved into a clear leader in the fragmented medical device segment of women’s healthcare due to 4 key factors: Extensive customer base Strong brand awareness Depth and breadth of product offerings Market focus Hospital/OR Competitors Esti
Slide 20: CooperSurgical Acquisitions
CooperSurgical Acquisitions Proven track record of execution & integration Completed 23 acquisitions in the past 10 years Strong focus on increasing margins through management expertise and superior manufacturing/distribution capabilities Recent acquisitions: Transaction Revenues at Year Company Pro
Slide 21: In Summary
oO Goper In Summary
Slide 22: The Cooper Companies Investment Highlights
The Cooper Companies Investment Highlights Five Key Takeaways 1. New products and healthy pipeline position Cooper to capture market growth 2. Significantly improved manufacturing capacity within CooperVision will support future growth 3. Solid top line growth, improving operating margins and reduce
Slide 23: Questions?
oO Goper QUESTIONS?
Slide 24: The Cooper Companies Contact Info
The Cooper Companies Contact Info Contacts: Corporate Headquarters: Robert S. Weiss 6140 Stoneridge Mall Road, Ste 590 President and Chief Executive Officer Pleasanton, CA 94588 Eugene J. Midlock www.coopercos.com Senior Vice President and Chief Financial Officer www.coopervision.com www.coopersurgi